Clinical trial · Observational
Non-surgical Management After NIT for dMMR/MSI-H GC
Non-surgical Management After Neoadjuvant Immunotherapy for Locally Advanced dMMR/MSI-H Gastric Cancer: WWWGC Phase II Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Gastric cancer is one of the most common cancers worldwide and has a poor prognosis Immunotherapy significantly improves the prognosis of gastric cancer. In resectable gastric/gastroesophageal junction adenocarcinoma (GAC/GEJA) C, mismatch repair deficiency (dMMR)/microsatellite instability (MSI-H) can improve survival, and immunotherapy can avoid chemotherapy or surgery. The dMMR/MSI-H status is the strongest predictive biomarker for the benefit of immunotherapy with anti-programmed death receptor 1 and its ligands (PD-1/PD-L1) in advanced solid tumors, especially metastatic gastric/gastroesophageal junction adenocarcinoma. The INFINITY study provides Durvalumab combined with Tremelimumab as a treatment option with significant benefits for preoperative treatment of dMMR/MSI GAC/GEJAC, as well as the feasibility of non-surgical treatment strategies for such gastric cancer patients At present, there are no studies related to Asian gastric cancer patients, which are worthy of further verification and exploration in Asian gastric cancer cohorts.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-surgical Management;dMMR/MSI-H Gastric Cancer;Neoadjuvant Immunotherapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Recurrence-free survival (RFS)
- timeFrame
- One year, three years, or five years after the end of immunotherapy
- description
- The recurrence-free survival time of gastric cancer patients
- measure
- Overall survival (OS)
- timeFrame
- One year, three years, or five years after the end of immunotherapy
- description
- The period from the start of randomization grouping in a clinical trial to the death of a patient for any cause
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Patients over 18 years old with advanced dMMR/MSI-H gastric cancer; Neoadjuvant therapy is needed (immunotherapy, chemotherapy + immunotherapy); The patient voluntarily and agreed to join the clinical research. Exclusion Criteria: Gastric cancer combined with invasion and metastasis; Gastric cancer combined with other malignant tumors; Gastric cancer combined with dysfunction of other organs; Unwilling to participate in clinical research.
References
Publications (0)
Data not yet available